CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

Index

A antigens 94
A transferase 94
ABO antigens 94, 97–98, 117–118
  antibody in AB-negative children 98
abruptio placenta 10
acanthocytes 410t
N-acetyl galactosaminyl transferase 94
activated partial thromboplastin time (APTT) 311
activated protein C (APC) 325
acute lymphoblastic leukemia (ALL) 390–391
  in utero origins 390–391
acute megakaryoblastic leukemia (AMkL) 392–393
acute myeloid leukemia (AML) 72, 391
adducin, erythrocyte cell membrane 45t
adenosine deaminase (ADA) deficiency 300, 301
adenovirus, thrombocytopenia 216
adhesion molecules
  ICAM-1 255
  ICAM-2 191, 255
  PCAM-1 191
ADP receptors 191
afibrinogenemia/hypofibrinogenemia 314–315
agglutinating tests, peanut/soya bean 98
agranulocytosis (Kostmann syndrome) 77–78, 265
alkylating agents, hypersensitivity of FA 74
alloantibodies 137
alloimmune hemolysis 135
alpha2-antiplasmin deficiency 318
alpha-fetoprotein 386
  elevated 11, 396
alpha-granules, platelets 191, 197
Alport/Epstein syndrome 224

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

amegakaryocytic thrombocytopenia (AMT) 77, 223–224
aminolevulinic acid synthase (ALAS-2) 80
amniocentesis 105–107
  algorithm 109t
  antigenic status 103
  and RhD immunization 101
amniotic fluid
  OD (bilirubin) 106t
  RhD typing 103
  spectroscopy 5
anemia
  assessment 47–48
    algorithm 53
  causes
    acquired RBC disorders 132t
    blood loss 48t, 48–49
    bone marrow failure 51t, 50–51
    cord damage 10
    DIC 50
    hemolysis 49t, 49–50
    hereditary RBC disorders 132t
    iatrogenic 49
    physiologic 47, 58, 133
    rubella 25
    toxoplasmosis 21
  congenital dyserythropoietic (CDA) 78–79
  differential diagnosis 47–51
    hemolytic CMV 25
  fetal, diagnosis 11
  fetal hemoglobin, reference ranges 105t
  pernicious 20
  therapy 51
    erythropoietin 51
    transfusion guidelines 351t
    transfusions 350–351
  see also anemia of prematurity; aplastic –; Fanconi –; hypoplastic –; physiologic –; sideroblastic –
anemia of prematurity 47, 58–63
  physiology 58
  therapy 58–60
  vitamin E deficiency 137
animal models, hematopoiesis (mouse embryo) 42t
ankyrin
  erythrocyte cell membrane 45t
  spherocytosis (HS) 140t
anti-A or -B agglutinating substance, IgM antibody 98
antibody
  measurement of titer 98–99
  see also Ig
antibody defects *see* B cell dysfunction
antibody deficiency
  associated with secondary immune disorders 290–291, 295–298
  management of infants 297–298
  management of mothers 298
  vaccine recommendations 298
antibody-mediated RBC destruction 99–100
anti-cardiolipin antibodies 15
anticoagulant therapy 331–334
  oral anticoagulants 332–333
    protocol 333t
  see also enoxaparin; heparin; reviparin
anticoagulant–preservative (AP) solutions 351–352
  safety 354–355
anticonvulsants
  causing anemia
  thrombocytopenia 205
  vitamin K deficiency 16
anti-D hemolytic disease 49
antigens
  expression by cord blood 94t
  expression in megakaryocytes 189t
  see also A; ABO; B; Duffy; H; HLA; HPA; Kell; Kidd (Jk); MNSs; N; Rh; S
antiglobulin test *see* direct antiglobulin test (DAT)
antimicrobials, and thrombocytosis 230
anti-phospholipid antibody syndrome 15
antiplasmin, in IDM 13
anti-Rh gamma globulin 5
antithrombin deficiency 326
aortic–gonadal–mesonephric (AGM) region, stem cells 41
aplastic anemia
  drug-induced 70
  Fanconi anemia 73
  hepatitis
  idiopathic 80
  work-up 81t, 81–82
apoptosis
  PMNs 256t
  polymorphonuclear leukocytes (PMNs) 258
Apt test 3
aquaporin, erythrocyte cell membrane 45t
arterial catheters, thromboembolic events 329–330
asphyxia, and thrombocytopenia 206
aspiration pneumonia 226
aspirin 17, 197
  see also NSAIDs

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

Auto Analyzer 104
autoimmune syndromes 15

B antigens 94
B cell deficiency diseases 289–291
  diagnostic approach 296t, 295–298
B cells
  humoral immunity 284–286
  numbers 284
    assessment 296
  subpopulations, neonates and infants 287t, 288t
Beckwith–Wiedemann syndrome 395, 396
Bernard–Soulier syndrome 195, 220, 224, 416
  platelet glycoproteins (PGPs) 417
beta/gamma switch, HbF 3
beta-methasone, lung maturation 108
BFU *see* burst-forming unit
Bhutani risk curves, bilirubin 134
bilirubin 110–113
  Bhutani risk curves 134
  OD of amniotic fluid 106t
  pigment assay 106–107, 108
  plasma indirect 113
  and platelet function 198
  unconjugated (indirect) 134
  see also jaundice/hyperbilirubinemia
bilirubin encephalopathy 114
Birbeck granules 397
bleeding time 194, 415–416
blood banks
  cord blood 376–379
    donor confidentiality 378
    private banking 377–378
    public banks 378
blood products, irradiation 272–273, 291, 300
blood sampling
  fetal *see* cord blood sampling
  minimizing loss 49, 58
    transfusions 351t
blood viscosity 172t, 173t, 174t, 175t
  capillaries 175t
  see also hematocrit
blood volume
  feto-placental circulation 10
  measurement 409
blueberry muffin rash 12, 24, 25, 387, 390
Bombay RBC phenotype 94, 270
bone marrow, stem cell transplantation 376
bone marrow failure 51t, 50–51
  causes 69t
  syndromes 70, 81, 223
bone marrow infiltration, thrombocytopenia 226
Brachmann–de Lange syndrome 81
BRCA1 and BRCA 2 75
breastfeeding
  and jaundice 111
  and UDPGT-1 111
bronchopulmonary dysplasia (BPD) 50, 351
Bruton's tyrosine kinase (Btk) 289
buffy coat transfusion, neutropenic neonatal sepsis 272
burst-forming unit–erythroid (BFU-E) 40
  yolk-sac 427t
burst-forming unit–megakaryocyte (BFU-Mk) 188t, 188–189

c-mpl *see* thrombopoietin (TPO) receptor
C-reactive protein (CRP) 282
calcium
  surface membrane depolarization 257
  transient rises in PMNs 257
cancer in newborns 385–397
  brain tumors 393
  epidemiology 385
  hepatic tumors 395–396
  histiocytosis 397
  leukemia 389–393
  neuroblastoma 387–389
  renal tumors 396
  retinoblastoma 395
  teratoma 386–387
  Wilms tumor 396–397
Candida spp.
  C. glabrata sepsis, thrombocytopenia 216
  thrombocytopenia 216
candidiasis, DHST 300
carbon monoxide, generation 134
cardiac defects, TAR syndrome 220
cardiac disease, cord stem cell transplantation 382
cardiopulmonary bypass (CPB), bleeding in 323
cardiopulmonary resuscitation, in HDN 110
cartilage–hair hypoplasia 73, 265
CATCH-22 syndrome, comparison with other syndromes 221t
catheter-related thromboembolic events 329–330
cell-mediated immunity defects 291–292
  diagnostic approach 299t, 298–302
cellular immunity 286–288
central venous lines, thromboembolic events 329
cerebral malformations 225

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

cervical tumors, Horner's syndrome 387
CFU *see* colony-forming unit
Chediak–Higashi syndrome 197, 270–271
chemiluminescence test 104
chemokines 284
  RANTES 284
chemotherapy
  in FA 74
  IUGR 15
  maternal malignancy 14–15
  in sideroblastic anemia 80
  thrombocytopenia 17
chloramphenicol, induction of aplasia 70
chorionic villus sampling (CVS)
  antigenic status 103
  and RhD immunization 101
chromosomal abnormalities, thrombocytopenia 217
chromosome fragility assay *see* diepoxybutane (DEB)
chronic granulomatous disease (CGD) 268–269
chronic leukemia 391–393
cinchona alkaloids, thrombocytopenia 204
circumcision, bleeding 311, 313, 320
citrate–phosphate–dextrose adenine (CPDA-1) 352, 354
  cord blood 377
Citrobacter diversus 215
clear cell sarcoma of kidney 397
coagulation defects, in cyanotic congenital heart disease 323–324
coagulation proteins *see* factors
cobalamin deficiency 19–20, 81
  hypokalemia 20–30
  macrocystic anemia 20
  megaloblastic anemia 19
  RDA and stores 20
  thrombocytopenia 226
collagen, platelet activation 193t
collagen defects 416
collagen receptor
  defects 197
  platelet function 191, 192, 193
collagen–epinephrine cartridge assay, platelets 416
colony-forming unit–erythroid (CFU–E) 40
  assays from preterm blood and BM 426t
  yolk-sac progenitors 427t
colony-forming unit–granulocyte erythroid macrophage megakaryocyte (CFU–GEMM) 40
colony-forming unit–granulocyte macrophage (CFU–GM) 255
  assays from preterm blood and BM 426t
  yolk-sac progenitors 427t
colony-forming unit–megakaryocyte (CFU–Mk) 188, 188t, 207
  assays from preterm blood and BM 426t
  cAMT 224
  TAR syndrome 222
colony-stimulating factors *see* G–CSF; GM–CSF; M–CSF
combined antibody and cellular immunodeficiencies 292–294
combined immunodeficiency disorders
  irradiation of blood products 300
  T cell dysfunction 291–292
common variable immunodeficiency (CVI), in pregnancy 298
complement cascade
  alternative/classical 281
  initiation by IgM 99
complement deficiencies 294
  diagnosis 303t, 302–303
complement system 281–282
  fetus 281–282
  preterm, term, adult 282t
complete blood counts (CBCs) 406
conceptional products, metastatic involvement 385
congenital dyserythropoietic anemia (CDA) 78–79
  treatment 79
  type I 78–79
  type II 79
  type III 79
  type IV 79
Coombs test 49, 53
  direct *see* direct antiglobulin test (DAT)
  indirect *see* indirect antiglobulin (Coombs) test (IAT)
copper deficiency 51, 80
cord blood
  antigen expression 94t
  for autologous transfusion 59
  banking 376–379
  and delayed clamping 356
  erythropoietin (EPO) 411, 411t, 412t
  hemoglobin 113
  HLA barriers 376
  thrombopoietin measurement 414
  transplantation *see* cord stem cell transplantation
  viscosity 172t, 174t, 175t
cord blood sampling 47, 105–107
  absolute lymphocyte count 300
  erythropoietin, and smoking 16
  hemoglobin values 47t
  historical aspects 5
  NAIT 214

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

percutaneous umbilical vein sampling (PUBS) 199
and RhD immunization 101
for transfusion 349
ultrasound-guided 107
cord stem cell transplantation 376–382
advantages of cord blood 376
banking of cord blood 376–379
centralized registry 379
'look forward' programs 379
public banks 378
screening 379
complications
graft-vs.-host disease (GVHD) 380
opportunistic infections 380
donors
CMV infection 378–379
availability 376
consent 377, 378
private banking 377–378
types 377
early experience 380
inborn errors of metabolism 381–382
neutrophil engraftment 380
patient age 381
unrelated transplantation 380–382
cordocentesis *see* cord blood sampling
corpus callosum, absence 225
corticosteroids 71, 77
Coumadin 17
cows' milk intolerance, TAR syndrome 220, 223
Coxsackie virus, thrombocytopenia 216
Creutzfeldt–Jakob disease (CJD), transfusion-related 368
Crigler–Najjar syndrome 111
cryoprecipitate 361–362
dose 315
indications 362–363
cutaneous erythropoiesis 12, 24t
cyanosis, methemoglobinemia 157
cyanotic congenital heart disease 323–324
transfusion 351t
cyclooxygenase inhibitors 197
cytochrome-b5 reductase *see* NADH-methemoglobin reductase
cytokine therapy 272–273
cAMT 224
cytokines 283
cytomegalovirus infection 23–25, 69
in cord stem cell transplantation 378–379
diagnosis 24
hematologic manifestations 24
megakaryocytes 216
post-transfusion 358, 368
cytopenias, causes 68–81

dacrocytes 410t
dapsone 135
DDAVP
dose 197
risk of seizures 198
delayed hypersensitivity skin testing (DHST) 293, 300
dengue virus, thrombocytopenia 216
dermal hematopoiesis 24t
desferoxamine 72
dexamethasone 17
oligohydramnios and growth retardation 212
di-(2-ethylhexyl)-phthalate (DEHP) 367
diabetes mellitus, maternal 12–13
see also infant of diabetic mother (IDM)
Diamond–Blackfan anemia 50, 68, 70–72
diagnosis 71
mechanism 71
presentation 71t
treatment and outcome 71–72
diepoxybutane (DEB) chromosome fragility assay 82
Fanconi anemia 219
TAR syndrome 220
DiGeorge syndrome 195, 220, 291
FISH analysis 300
treatment 301
2, 3-diphosphoglycerate (2, 3-DPG) 3, 46, 350
regeneration in PRBC 352
direct antiglobulin test (DAT) 53, 118, 135
ABO incompatibility 140
directed donor transfusions 355
discocytes 410t
disseminated intravascular coagulation (DIC) 29, 100, 321
clinical presentation and diagnosis 322
etiology 321
hemorrhagic complications 327
hemostatic complications 361
management 29, 322
fresh frozen plasma 227
mechanism 321–322
schistocytic anemia 136
thrombocytopenia 200, 206
in TMD 392
DNA-based testing, NAIT 211, 212
Dohle bodies 81
Doppler ultrasound 105

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

Down syndrome (trisomy 21) 81, 271
  leukemia 391
  thrombocytopenia 217
drug-associated disorders
  aplasia 70
  hemolytic anemia 135
  platelet function defects 197–198
  thrombocytopenia 205t, 204–205
drugs, effects on PMNs 263
Dubin–Johnson syndrome 311, 315
Dubowitz syndrome 80
Duffy antigen 95, 99, 118–119
dyskeratosis congenita 76–77, 265
  and thrombocytopenia 219
dyskerin 76

E-selectin, endothelial cells 258
echinocytes 146, 410t
echovirus-11 27
Ehlers–Danlos syndrome 416
electrophoresis, hemoglobin 410
ELISA test, anti-RhD 104
elliptocytes *see* hereditary elliptocytosis (HE)
elliptocytosis (HE) 138, 138t, 141–142
Embden–Meyerhof pathway 45, 146
embryonal carcinoma 386
endocardial thrombosis syndrome 226
endothelial cells, surface antigen expression 255
enolase 45
enoxaparin
  dosage 332t
  monitoring nomogram 333t
  prophylaxis 332t
enteroviral infections 26–27
  hematologic manifestations 27
enzymopathies 17, 142
eosinophilia 267–268
  associated conditions 268t
  preterm infants 267
eosinophils, adhesion 259
epinephrine receptor, neonatal platelets 192, 195
epsilon-aminocaproic acid (EACA) 218
Epstein–Barr virus infection 30
  thrombocytopenia 216
erythema infectiosum 27, 68
erythroblastosis fetalis
  historical aspects 4–5
  see also hemolytic disease of newborn (HDN)
erythroblasts, nucleated 41
erythrocytes 42–47
  antigen expression in cord blood 94t
  antigens and antibody response 96–99
    see also named antigens
  biochemistry 45–47
  Bombay phenotype 94, 270
  cell membrane 45, 45t
    components 138–139
    glycoprotein 136
  cord 45
  differential count, newborns 410t
  immature 410t
  increased destruction 134–135
  interaction with fibrin 136
  life span 132
  maternal medications 17
  mean cell volume (MCV) 406
  measurements 406–409
  metabolism, summary 143t
  morphology 409–410
  nucleated 133
  osmotic fragility test 139–141
  red cell distribution of width (RDW) 406
  T-activation 136
  transfusions *see* red blood cell transfusions
erythrocytes, fetal, in maternal blood 11
erythroid progenitors (Ery-CFC) 41
erythroid shapes, differential count in newborns 410t
erythropoiesis 40–42
  cutaneous 12, 24t
  development 41t
  fetal, suppression 359
  growth factors 41t
  and hemoglobin switching 44t
  see also hematopoiesis
erythropoietin (EPO)
  cord blood 411
    preterms 412t
    various gestational ages 411t
  diminished synthesis 350
  and HbF 46
  in IDM 13
  measurement 411
  recombinant 355–356
    early therapy 355
    European Study group trial 356
    US rHuEPO vs. CAP trial 350, 351t
  and smoking 16

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

and thrombocytosis 229
treatment of anemia of prematurity 51
see also rhEPO
ethanol, and platelet function 198
Ewing's sarcoma family of tumors (EFT) 394
exchange transfusion 107–108, 113–115, 356–358
bilirubin values 118
calculation of blood needed 354t
complications 357
donor with sickle trait 154
fetal 358–359
followed by thrombocytopenia 214
G6PD deficiency 145, 146
in HDN 214, 356–358
historical aspects 5
method 358
neutropenic neonatal sepsis 272
outcome 115
partial 357–358
prenatal 114–115
survival rates 357
and thrombocytopenia 206
extracorporeal circulation, Waring blender effect 50
extracorporeal membrane oxygenation (ECMO) 198, 362–363
blood bank support 349, 363
TAGVHD in 366

factor V, Leiden mutation 325–326
factor deficiencies 311–318
V 315
VII 315–316
VIII 312–313
see also von Willebrand factor
X 316–317
XI 317
XII 310
XIII 317–318
familial multiple 318
properties of factors 312t
replacement therapy in severe hemophilia 314t
summary 311t
see also hemorrhagic disorders
factors I to XIII
available concentrates 313t
concentration in congenital deficiencies 311t
concentration in healthy newborns 311t
properties 312t
Fanconi anemia 50, 73–76
comparison with other syndromes 221t
diepoxybutane chromosome fragility assay 82
genetics 74–75
international registry 82
presentation 73t
thrombocytopenia 218–219
treatment 75–76
favism 145
Fc receptors 99
anti-HLA antibody 100
binding tests 104
FcgammaRII 100
IgG-induced RBC destruction 100
mononuclear phagocytes 263–264
polymorphonuclear leukocytes (PMNs) 260
Fechtner syndrome 224
ferritin 17
infants 1–7 months 412t
measurement 411–413
in pregnancy 18
in preterm infant 61
rhEPO-stimulated erythropoiesis 61, 62
fetal transfusion *see* exchange transfusion
fetal–maternal alloimmune thrombocytopenia (FMAIT) 208
fetal–maternal hemorrhage (FMH) 10–11, 96
anti-RhD antigenic sites 100
causes 11t
gestational age 96
and maternal isoimmunization 101–102
feto-maternal transfusion 3, 5
feto-placental unit
blood volume 10
hemorrhagic disorders 10–14
fibrinogen
afibrinogenemia/hypofibrinogenemia 314–315
concentrate 313t
deficiency 314–315
in DIC 322
structure 314
fibrinogen receptor 192
fibronectins 282
fibrosarcoma, congenital 395
fifth disease 27, 68
filters
leukodepletion filters 353
microaggregate filters 353
flow cytometry 82, 102, 104
platelet function 194–195
platelet surface receptors 417
reticulocyte count 133, 410

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

fluorescence activated cell sorting (FACS) 82, 103
fluorescent treponemal antibodies (FTA-Abs) 23
folate 18–19
  measurement 413
  supplementation 19
folate deficiency 19
folic acid, and erythropoiesis 141
free radicals 46
  Fanconi anemia 74
  iron-induced diseases 63
fresh frozen plasma (FFP) 361
  contraindications 362
  donor retested 361
  dose 314, 315, 362
  indications 361–362
  and NEC 358
  whole blood reconstitution 354t, 353–354
Friedreich's ataxia 81
fungal infection, thrombocytopenia 216
Fy, a and b antigens 118–119

G-CSF, treatment with 273, 364
galactokinase 45
galactosemia 271
galactosyl transferase 94
gangrene, perinatal 13
GATA 1 locus 225, 392
genotype analysis 82
gestational diabetes 12
giant hemangioma syndrome 217–218
Gilbert syndrome 111–112, 141, 145, 311, 315
Glanzmann thrombasthenia 196t, 195–196, 416, 417
globins 43, 43t, 147–148
  alpha and beta abnormalities 147–148
  alpha globin synthesis 149
  beta globin synthesis 151
glucocorticoids, lung maturation 108
glucose phosphate isomerase (GPI) deficiency 146–147
glucose-6-phosphate dehydrogenase (G6PD)
  function 142–146
  normal/wild-type 142
  racial variants 145
  variants 142
glucose-6-phosphate dehydrogenase (G6PD) deficiency 17, 142–146, 270–271
  causes of hemolysis, drugs 144t
  diagnosis 144–145
  hyperbilirubinemia 145
  mutations
    A-variant 145
    Mediterranean variant 144, 146
  neonatal screening 145
  pyknocytosis 137
  transfusion medicine 146
glucuronyl transferase, reduction 134
glutathione 142
glutathione defective metabolism in phagocytes 271
glutathione peroxidase 45
  deficiency 271
glycogen storage disease IB 271
glycophorin A 95–96
glycoproteins
  erythrocyte cell membrane 136
  see also platelet glycoproteins (PGPs)
GM-CSF
  development of monocytes 258
  treatment with 272
graft-vs.-host disease (GVHD) 72, 75
  cord stem cell transplantation 380
  transfusion-associated TAGVHD 355, 365–366
granulocyte transfusion 272, 363–364
  vs. immunoglobulin replacement therapy 364
granulocytes, irradiation 272
gray baby syndrome 70
gray platelet syndrome 197, 224
growth factors, erythropoiesis 41t

H antigen 94
Haemophilus influenzae infection 216
  splenectomy 141
Hand–Christian–Schuller disease 397
haptoglobin, assay 134–135
  beta-hCG 386
hearing impairment, and thrombocytopenia 225
Heinz bodies 45, 48, 154
  hemolytic anemia 137
HELLP syndrome 14
hemangioepithelioma 395
hemangiomas 50
  eyelid 218
  giant hemangioma syndrome 217–218
  and thrombocytopenia 217
hematocrit
  capillary and venous blood 173t, 409t
  hyperviscosity 172t, 173t, 174t, 175t
  infant of diabetic mother (IDM) 13

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

measurement 406
capillary samples 406
timing 406, 409
reduction, partial ET 358
hematocytometers 2
hematopoiesis
current hypothesis 40
dermal 24t
hepatic 41, 42t, 43t, 393
and megakaryocytopoiesis 187–190
mesoblastic 43t
model (mouse embryo) 42t
myeloid 43t
phases 40, 43t
yolk-sac 42, 42t, 254–255
see also erythropoiesis
hemocytoblasts 40
hemoglobin 43–44
abnormal 410
alkali denaturation test 3
carriers of variants 167–168
cord blood 113
preterms 412t
fetal anemia, reference ranges 105t
free plasma 134
globin chain development 43t
HPLC 153
isoelectric focusing (IEF) 164, 411
measurement 406
heelstick vs. venous 406
mean cell hemoglobin concentration (MCHC) 406
oxygen equilibrium curves 46t
separation by electrophoresis 410
and smoking 16
switching 44t
synthesis, fetal and infant 148t
unidentified variants 168
screening 168t
hemoglobin A (HbA)
oxygen equilibrium curves 46t
transition from HbF 46, 46t
hemoglobin Barts 147, 149, 150–151
and MCV 406
screening 166–167
hemoglobin Constant Spring 148, 150, 151
genotypes 149t, 151
hemoglobin E/beta thalassemia 152–153, 166
hemoglobin F (HbF) 3
beta/gamma switch 3
characteristics 147
concentration in newborn 133
and erythrocyte life span 132
hereditary persistence 11
normal cord values 47t
normal values 47
oxygen affinity 46
oxygen equilibrium curves 46t
'physiologic nadir' 47
reference ranges, anemia and normal 105t
screening 166t, 164–166, 167t
synthesis 42, 148t
iron requirement 61
transition to HbA 46, 46t
types observed in newborn screening 153t
hemoglobin F-Poole 155
hemoglobin FM-Fort Ripley 156
hemoglobin FM-Osaka 156
hemoglobin Gower-1 and -2 43
hemoglobin H disease 149–150
detection 151
hemoglobin Hasharon 155
hemoglobin M disorders 156
hemoglobin Portland 43, 150
'hemoglobin switching' 43
hemoglobin–haptoglobin complexes 134–135
hemoglobinopathies 147–155
carriers 167t
historical aspects 3
non-sickle 166
screening 166t, 163–168
unstable 154–155
see also sickle cell syndromes; thalassemia syndromes
hemolysis
alloimmune 135
see also hemolytic disease of newborn (HDN)
severe immune-mediated, and transfusion 365
hemolytic anemia 132
acquired 135–138
causes
acquired RBC disorders 132t
hereditary RBC disorders 132t
drug-associated 135
increased RBC production
laboratory features 133–135
in SCD 165
hemolytic disease of newborn (HDN) 91–119
amniotic fluid OD 106t
antibodies 92t

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

hemolytic disease of newborn (HDN) (*cont.*)
antigen-specific considerations 116–119
ABO 117–118
Duffy 118–119
Kell 117
Kidd (Jk) 119
MNSs 119
RhCcEe 116–117
RhD 116
third world 49
causes 49t
fetal hemolysis by maternal antibody 96–100
interactions of antibody with RBC antigens 99–100
maternal antibody response 96–99
maternal exposure to fetal RBC antigens 96
transport of antibody across placenta 99
hemoglobin values, reference ranges 105t
incidence 91
management, first affected fetus, algorithm 109t
maternal risk factors 97t
paternal testing 103, 109t
postnatal intervention 108–115
at delivery 108–109
management of newborn 110
partial/whole/later exchange transfusion 114t
see also exchange transfusion; jaundice/hyperbilirubinemia
prenatal intervention 100–108
exchange transfusion 113–115
invasive monitoring 103–108
prevention of isoimmunization 100–102
prenatal management algorithm 109t
and thrombocytopenia 214–215
hemolytic transfusion reactions 364–365
hemolytic uremic syndrome 29, 50, 136
atypical 136
in pregnancy 202
hemophilia
differentiation from hemorrhagic disease of newborn 6
factor deficiencies, replacement therapy 314t
hemorrhagic disease of newborn
differentiation from hemophilia 6
historical aspects 5–6
hemorrhagic disorders 310–325
acquired 319–324
clinical presentation
congenital 310–318
in cyanotic congenital heart disease 323–324
diagnosis 311
intracranial hemorrhage (ICH) 324–325
treatment 311
hemosiderin, urinary 135
hemostasis, maternal medications 16
hemostatic abnormalities 310–334
hemostatic proteins 310
heparin
in ECMO 363
large vessel thrombosis 322
LMW, prophylactic 327, 328, 331
unfractionated (UFH) 322, 331
administration protocol 332t
heparin-induced thrombocytopenia (HIT) 17, 205
hepatic failure, platelet function 198
hepatic hematopoiesis 41, 42t, 393
hepatic tumors 395–396
hepatitis
aplastic anemia 70
bleeding in 323
hepatitis A–C
transfusion risk 367–368
estimates 367t
hepatoblastoma 396
hereditary elliptocytosis (HE) 138, 138t, 141–142
hereditary pyropoikilocytosis (HPP) 138t, 141
hereditary RBC disorders 132t, 138–142
hereditary spherocytosis (HS) 138, 138t, 140t, 139–141
Hermansky–Pudlak syndrome 197
herpes simplex infection 26
delay in cellular immunity 288
memory T cells 287
suppression of CFU-Mk 216
hexokinase (HK) deficiency 147
hexosemonophosphate (HMP) shunt 142
histiocytosis 397
HIV infection 29–30, 70, 292
diagnosis and management 302
hematologic manifestations
HIV-1 p24 antigen testing
thrombocytopenia 202, 216
transfusion-related 367
risk estimates 367t
TAGVHD 366
HLA antigens
DR
paternal 100
super-antigen DRw52 210
and engraftment 365

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

and NAIT 210
see also major histocompatibility complex (MHC)
Holt–Oram syndrome 220
comparison with other syndromes 221t
homocysteine
and cobalamin 19
in folate deficiency 19
in IDM 13
homovanillic acid (HVA) 387
Horner's syndrome 387
Howell–Jolly bodies 48
Hox A11 gene, thrombocytopenia and radio-ulnar synostosis 223
Hoyeraal–Hreidarsson variant, dyskeratosis congenita 76
HPA, classification 209, 209t
HPA-1a antigen 208, 210
anti-HPA-1a antibody 211
feto-maternal incompatibility 359
and risk 212
HPA-1b antigen 208, 209
and risk 212
HPA-2a antigen 207
HPA-4b (Yuka) 211
HPA-5b antigen 359
HTLV I and II, transfusion risk 367, 367t
human parvovirus B19 27–28
human platelet antigens *see* HPA
humoral immunity 284–286
hydralazine, thrombocytopenia 204–205
hydrops fetalis
with anemia 47
causes 68
and erythroblastosis fetalis 4
homozygous alpha thalassemia 150–151
thalassemias 3
TMD 391
treatment 51, 110
ultrasound 105
hyper-IgM syndrome (HIM) 265, 290
immunoglobulin replacement therapy 298
hypereosinophilia, with SCID 294
hyperglycemia
fetal 12
maternal 12
hyperkalemia, following PRBC 366
hyperkalemic arrest, transfusion-related 366
hypertension in pregnancy 13–14, 204
see also infant of hypertensive mother (IHM); preeclampsia
hyperthyroidism, and thrombocytopenia 226
hyperviscosity, cord blood 172t, 173t, 174t, 175t
hypocalcemia
DiGeorge syndrome 195, 220, 291, 300
transfusion-related 366
hypogammaglobulinemia of infancy (THI) 290, 296–297, 298
in trisomies 291
hypogammaglobulinemia of prematurity 297
hypoglycemia
rebound 366
transfusion-related 366
hypokalemia, cobalamin deficiency 20
hypoplastic anemia 68–82
hypothermia 226
hypovolemia, in TTS 11

ICAMs *see* adhesion molecules
idiopathic thrombocytopenia (ITP), maternal 202–203, 359
Ig, intravenous Ig 108, 115
antibody deficiency 297–298
blood–brain barrier 298
in NAIT 211–212, 214
prevention of infections 297–298
replacement therapy in SCID 301
IgA 286
maternal deficiency 298
normal values, term infants to 3 years 285t
profiles in immunodeficiency disorders 295t
values
preterm infants: 25–28 w gestation 283; 29–32 w gestation 284
IgE, profiles in immunodeficiency disorders 295t
IgG 284–285
anti-D, prevention of maternal isoimmunization 100
deficiency
age of documentation 289
ill preterm infants 285
and maternal antibody deficiency 284
maternal antibody half-life in fetus 285
NAIT antibody, and thrombocytopenia 207
normal values, term infants to 3 years 285t
platelet-associated (PAIgG), and thrombocytopenia 206, 215
profiles in immunodeficiency disorders 295t
subclasses 286
values
preterm infants: 25–28 w gestation 283; 29–32 w gestation 284

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

IgG anti-RBC antibody 98
  IgG-induced RBC destruction and Fc receptors 100
  production 96
  subclasses 99
IgM 285–286
  anti-A or -B agglutinating substance 98
  anti-T antibodies 136
  antibody in AB-negative children 98
  complement cascade 99
  hyper-IgM syndrome (HIM) 265, 290, 298
  normal values, term infants to 3 years 285t
  production 97
  profiles in immunodeficiency disorders 295t
  uninvolved in HDN 99
  values
    preterm infants: 25–28 w gestation 283; 29–32 w gestation 284
immune globulin *see* immunoglobulin replacement therapy
immune hemolytic anemia, maternal risk factors 135
immune reconstitution, median absolute values 381t
immune system, immaturity 281t, 280–288
immune thrombocytopenic purpura (ITP), maternal 202–203, 359
immunity
  cellular 286–288
  humoral 284–286
  innate 280–284
  immunodeficiency, centromeric heterochromatin and facial abnormalities (ICF) syndrome 290
  cytogenetics 299
immunodeficiency disorders 280–303
  B cell dysfunction 289–291, 295–298
  classification 289t
  diagnosis and management 294–303
  management
  single gene defects 297t
  T cell dysfunction 291–292
  vaccine recommendations 301
  see also specific named disorders
immunoglobulin replacement therapy
  vs. granulocyte transfusion 364
  hyper-IgM syndrome (HIM) 298
immunoglobulins *see* Ig
inborn errors of metabolism, cord stem cell transplantation 381–382
indirect antiglobulin (Coombs) test (IAT) 98, 103, 104
  Marsh score 104
indomethacin
  effect on PMNs 263
  prevention of IVH 325
indomethicin 197
  see also NSAIDs
infant of diabetic mother (IDM) 12–13
  polycythemia 12
  thrombocytopenia 13, 225
  thrombosis 55
infant of hypertensive mother (IHM) 14
  neutropenia 14, 265
  polycythemia 14
  thrombocytopenia 14
infant of hypertensive mother (IHM) *see* hypertension in pregnancy
infantile poikilocytosis 141–142
infections
  congenital 68–70, 135–136
  intrauterine 20–30
  thrombocytopenia 215–216
  transfusion-related 367–369
innate immunity 280–284
integrins
  deficiency, in leukocytes 269
  platelets 191, 193
  PMNs, upregulation 255
interferon alpha-2a, therapy 218
interferon gamma
  activation in mononuclear phagocytes 264
  effect on PMNs 263
  and infection 288
interferons, production 283
interleukins
  IL-1, and thrombocytopenia 217
  IL-3 72
  IL-6 223
  production 283
intracranial hemorrhage (ICH) 324–325
  clinical presentation 324
  in ECMO
  full term newborns 324
  platelet disorders 359
  platelet transfusion-related 359
  preterm newborns 324–325
  thrombolytic therapy-related 334
intracranial *see* intraventricular
intraperitoneal transfusion, historical aspects 5
intrauterine growth retardation (IUGR)
  and chemotherapy 15
  OD of amniotic fluid 106t

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

intrauterine infections 20
intrauterine transfusion *see* exchange transfusion
intravascular hemolysis, anemia 118
intravascular transfusion 358
  vs. intravascular exchange transfusion 358
intraventricular hemorrhage (IVH)
  enteroviral infections 27
  preterm newborns 324
  smoking 16
  and thrombocytopenia 204, 206, 211
    prevention 212
    previous sibling 213
    prognosis 214
intrinsic factor 19
iron
  fetal 18
  perinatal acquisition 61
  postnatal sources 61
  RDA during pregnancy 18
iron deficiency 17–18
  LBW infants 18
  measurement 411–413
iron overload 72
iron saturation ratio 18
iron status of preterm infants 50, 61–63
  cut-off value 61, 62
  long-term status 63
  markers 61
  measurement 61
iron supplementation
  enteral 62
  in HIV 29
  oral high-dose 62
  parenteral 62–63
    toxicity 63
  in rhEPO therapy 60
isoelectric focusing (IEF) 164, 411
isohemagglutinin titer, to ABO antigens 296, 349

Jacobsen syndrome 217
jaundice/hyperbilirubinemia
  approach 113t
  defined 111
  HDN 110–113
    ABO HDN 118
    diagnosis and management 112–113
    Gilbert syndrome 111–112
  in HS 139
  management 141
  pathophysiology 110–113
  physiologic 134
  PK deficiency 146
  prevention in G6PD 145
  see also hemolytic disease of newborn (HDN)
Jk antigen 95, 119
juvenile myelomonocytic leukemia 391

kaposiform hemangioendothelioma 217
Kasabach Merritt syndrome (KMS) 217–218
Kell antigen system 92, 94–95, 99, 117
keratocytes 410t
kernicterus 112–113
Kidd (Jk) antigen 95, 99, 119
Klebsiella infection 215, 363
Kleihauer–Betke technique 11
  modification for HbF 102
knizocytes 410t
Kostmann syndrome (agranulocytosis) 77–78, 265

L-selectin
  mononuclear phagocytes 259t, 263
  PMNs 255, 258, 259
lactic dehydrogenase (LDH), marker of accelerated RBC destruction 134
lactoferrin 282–283
Langerhans cell histiocytosis 397
large vessel thrombosis, heparin 322
LBW infants, iron deficiency 18
Letterer–Siwe disease 397
leukemia 389–393
  ALL 390–391
  AML 72, 391
  chronic 391–393
  clinical presentation 390
  diagnosis 390
  Down syndrome (trisomy 21) 391
  juvenile myelomonocytic leukemia 391
  maternal, and cancer in newborns 386
  transient myeloproliferative disorder 390, 391–393
leukemia cutis 390
leukemoid reactions 390
  TAR syndrome 220
leukocyte adhesion deficiency (LAD-1 and -2) 269–270
leukocytes
  and maternal medications 17
  transfusions 272
leukocytosis, TAR syndrome 220
leukodepletion filters 353, 368
leukodystrophies, cord stem cell transplantation 382
Li–Fraumeni syndrome 395

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

Liley curve 106–107
lipid emulsions, effect on PMNs 263
lipopolysaccharide binding proteins 283
LISS antiglobulin technique 118
Listeria infection 215, 283
liver disease, bleeding in 323
lumiaggregometry 416
lung injury, transfusion-associated (TRALI) 365
lupus anticoagulant 15
lupus erythematosus
  neonatal 203
  neonatal syndrome (NLE) 203
lymphocytes
  [K] ADCC assay 104
  subpopulations, neonates and infants 287t, 288t
  see also B cells; T cells
lysosomal assembly defects 197
lysosomal storage disorders 271

M-CSF, development of monocytes 258
Mac-1 deficiency (leukocyte integrin deficiency, LAD-1) 269–270
macrocystic anemia, cobalamin deficiency 20
macrothrombocytopenias 224
major histocompatibility complex (MHC), class II deficiency 291–292
malaria, transfusion-related 368
Malassezia fungemia, thrombocytopenia 216
malformations, and chemotherapy 15
malignancy, maternal 17
malignant melanoma, metastasis 15
mannose binding proteins 283
  alpha-mannosidosis 271
Marfan syndrome 416
Marsh score 104
maternal antibodies, HDN 92t
maternal isoimmunization, prenatal interventions in HDN 100–102
maternal malignancy 14–15
  and cancer in newborns 385–386
maternal medications 16–17
maternal RBC transfusion history 96
maternal risk factors 12–30
  drug-associated 135
  HDN-associated 97t
  immune hemolytic anemia 135
May–Hegglin anomaly 224
mean corpuscular volume (MCV) 133
  screening 168
mean platelet volume (MPV)
  in infection 215
  normal 191
  normal newborn 192
meconium aspiration syndrome 226
Mediterranean macrothrombocytopenia 224
megakaryocytes
  antigen expression 189t
  classification 189
  colonies in newborn 189–190
  measurement 413–414
  polyploidization and maturation 190t
  proplatelets 189t, 190
  see also megakaryocytopoiesis; platelet(s)
megakaryocytopoiesis 188t, 187–190
  differention markers 189
  platelet formation 190
megaloblastic anemia, cobalamin deficiency 19
2-mercaptoethanol 98
mesoblastic nephroma 396
metabolic disorders, thrombocytopenia 225–226
metaphyseal dysostosis 76
metastatic involvement, conceptional products 385
methemoglobinemia 45, 155–157
  acquired 155–156
  congenital 156
  cyanosis 157
  renal tubular disease 156
  treatment 157
methylene blue 157
methylmalonic acid, folate deficiency 413
mevalonic acidemia 226
microangiopathic (schistocytic) anemias 136
middle cerebral artery (MCA), velocity studies 105, 107
mitochondrial DNA, Pearson syndrome 72
Mk-CSA 230
MLL gene 390
MN blood group system 95–96
MNSs antigen, HDN 119
monocyte monolayer adherence assay (MMA) 104
monocytes *see* mononuclear phagocytes
mononuclear phagocytes
  abnormal/dysfunction 268–271
    management
  activation by INF-gamma 264
  adults 258
  C3b receptor expression 263
  candidacidal ability 264
  Fc receptor expression 263–264

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

L-selectin expression 263
microbicidal ability 264
myeloperoxidase deficiency 270
neonates 258–263
as precursor cell 258
similarity to PMNs 258
monosomy-7 syndrome 391
Montreal platelet syndrome 224
mucopolysaccharidoses, cord stem cell transplantation 382
myelodysplasia 391
myeloid growth factors, PMN storage pools at delivery 254
myeloperoxidase
deficiency 270
in PMNs 260
myelopoiesis
at delivery 254
placental inhibitor 265

N antigen, HDN 119
NADH-methemoglobin reductase 155
deficiency 156–157
NADPH oxidase
activation by PMNs 256t
deficient/absent 268
PMNs 257
necrotizing enterocolitis (NEC) 136, 137
and FFP 358
and thrombocytopenia 206, 216–217, 227
neonatal alloimmune thrombocytopenia (NAIT) 201, 207–214
antigens associated 208–209, 209t
assessment of risk 212
clinical presentation 207–208, 208t
complications 214
diagnostic approach 227–228, 229t
differential diagnosis 211
DNA-based testing 211
genetic diagnosis of infant at risk 212
immune response 210–211
incidence and prevalence 209–210
mechanism 206t
in mothers 202
platelet count 207
therapy 211–212
platelet transfusions 360t, 359–361
prenatal 212–214
tailored to risk categories 213, 214t
neonatal autoimmune thrombocytopenia (NITP) 361
neonatal lupus *see* lupus erythematosus (NLE)
neuraminidase 136
neuroblastoma 387–389
diagnosis 387–388
presentation 387
screening 389
staging 388, 388t
treatment 389
neutropenia 264–267
acquired forms 265
algorithm for treatment 259t
associated conditions 265t
causes in neonates 259t
defined 363
delayed separation of umbilical stump 270
infant of hypertensive mother (IHM) 14, 265
and infection 265–267
inherited congenital 265
neutropenic neonatal sepsis 272
neutrophilia 267
associated conditions 267t
neutrophil
counts
preterm infants, 0–60 hours, and 2.5–28 days 423t
term and preterm infants: 0–60 h 419; 60–120 h, and 5–28 days 420
engraftment, cord stem cell transplantation 380
storage pool 363
see also mononuclear phagocytes; polymorphonuclear leukocytes (PMNs)
nitric oxide 198
nitrites 155
nitroblue–tetrazolium (NBT) test 268, 269t
Noonan syndrome 81
NSAIDs 204
nutritional deficiencies, maternal 17–20

oligohydramnios, in TTS 12
oligohydramnios and growth retardation, dexamethasone 212
Omenn syndrome 294
flow cytometry 300
ophthalmoplegia, and thrombocytopenia 225
opsonins
PMNs 261
preterm infants 281
production 281
osteopetrosis 78
oxygen delivery, postnatal changes 46–47

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

P antigen 27
P-selectin 191
  endothelial cells 258
packed red blood cells (PRBC)
  in ECMO 363
  formulae for transfusion 354t
  guidelines 351t
  hyperkalemia 366
  infusion issues 353
  optimal volume
  partial ET 357–358
  shelf life 352
  whole blood reconstitution 353–354
  see also red blood cell transfusions
pancytopenia
  congenital 218
  Fanconi anemia 73
  workup 81–82
Pappenheimer bodies 48
Paris–Trousseau syndrome 224
parvovirus B19 27–28, 68–69
  fetal and perinatal transfusions 69
  thrombocytopenia 216
paternal HLA DR antigens 100
paternal RBC transfusions 355
paternal testing, HDN 103
PCAMs *see* adhesion molecules
Pearson syndrome 72–73
pentose phosphate pathway 45
pentoxifylline, effect on PMNs 263
percutaneous umbilical vein blood sampling *see* cord blood sampling
peripheral blood smear 133
  elliptocytosis 141
  examination procedure 48
  pyknocytosis 137–138
pernicious anemia 20
PFA-100®, measurement of hemostasis 194
phagocytes *see* mononuclear; polymorphonuclear leukocytes
phagocytosis
  frustrated 257
  in PMNs 261
phenylketonuria, screening 163
phorbol myristate acetate (PMA), NBT reduction 268
phosphatidylglycerol, amniotic fluid 108
phosphatidylserine (PS) 195
phosphofructokinase 45
phosphofructokinase (PFK) deficiency 147
phosphoglycerate kinase (PGK) 45
  deficiency 147
phospholipase C (PLC) 193
phototherapy
  bilirubin levels 114, 115, 118
  G6PD deficiency 145
  platelet function 198
physiologic anemia 47, 133
  hemoglobin F (HbF) 47, 58
  transfusions 350
physiologic hyperbilirubinemia 134
placenta, immune function 283
placenta previa 10
placental abnormalities, thrombocytopenia 205
placental blood
  autologous transfusion 356
  heparinized 356
placental infarction 200
plasma volume, measurement 409
plasmapheresis 108
Plasmodium vivax 95
plasticizers, di-(2-ethylhexyl)-phthalate (DEHP) 367
platelet activating factor (PAF), in NEC 217
platelet activation, by collagen 193t
platelet adhesion 416
platelet anatomy 191
  normal newborn 192
platelet count 198, 413–414
  fetus 199, 200t
  full term 198, 198t, 199t
  infant factors 205–215
  maternal factors 200–203
    diagnosis and incidence 201t
    drug-associated thrombocytopenia 204–205
    drugs 204–205
    incidence (fetal/neonatal) 202t
  platelet transfusions 227–228, 359–361
    intrauterine 214, 359
  preterm infant 198, 199t
  thrombocytosis 228t, 228–229, 230
platelet formation 190t
  production 413–414
platelet function 192, 414–417
  adhesion 193
  aggregation 193, 194
  assessment 194
  bleeding time 194, 415–416
  flow cytometry 194
  normal newborn 194–195

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

reactivity in IDM 13
shape changes 192
platelet function defects 195–198, 228
collagen receptor defects 197
congenital platelet activation defects 197
drug-induced 197–198
and intracranial hemorrhage (ICH) 359
other conditions 198
presenting in older children 196–198
secretory disorders 197
therapy 198
platelet glycoproteins (PGPs) 189–190, 191, 192
Bernard–Soulier syndrome 417
binding 193
binding by collagen 193t
classification 209t
Glanzmann thrombasthenia 195, 417
HPA antigens 209
vWFR defect 195
platelet release 416
platelet size 191–192
giant 413
normal newborn 192
platelet structure 190–192, 413–414
alpha-granules 191, 197
normal newborn 192
platelet surface 191
normal newborn 192
platelet transfusions 198, 227–228, 359–361
choice of product 360
congenital platelet activation defects 197
Glanzmann thrombasthenia 196
guidelines 360t
indications 227–228
intrauterine 214, 359
maternal platelets 360
and NAIT 211–212, 213–214, 360t, 359–361
neonatal alloimmune thrombocytopenia 359–361
prophylactic 359
random donor 361
platelet unit, standard 360
platelet pheresis 360
Pneumocystis carinii pneumonia (PCP, prophylaxis 298
poikilocytosis 142
polychromatophilic cells 48
polycythemia
historical aspects 2
infant of diabetic mother (IDM) 12, 225
infant of hypertensive mother (IHM) 14
and smoking 16
and thrombocytopenia 226
polycythemia–hyperviscosity syndrome 11–12
complications 12, 13
partial ET 358
polyhydramnios
in HDN, indication for delivery 109
in TTS 12
polymorphonuclear leukocytes (PMNs) 254–273
activation 257
adhesion 258–260
anti-viral and cytotoxic activity 263
apoptosis 258
chemoattractants 257
receptors 257
chemotaxis 260–261
drug effects 263
dysfunction
management 272–273
sites of abnormality 259t
exudation 257
Fc receptor function 260
half-life 255
L-selectin 255, 258, 259
myeloperoxidase content 260
normal function
adults 255–258
components 256t
neonates 258–263
phagocytosis and bacterial killing 261
numbers 264
VLBW infants 264
opsonins 261
primary granule markers 260
primary granules 260
production 254–255
reactive maternal antibodies 265
respiratory burst activity 262
rolling behaviour 255–257, 258
signal transduction 261
storage pool 254–255
circulating/marginated 255
stress effects 261–262
structure
cytoskeleton 261
secondary granules 255, 257, 260
tertiary granules 260
surface antigen heterogeneity 260

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

polymorphonuclear leukocytes (PMNs) (*cont.*)
surface receptor expression 260
viability 262
portal vein thrombosis 329
pre-eclampsia/eclampsia
HELLP syndrome 14
thrombocytopenia in newborn 204
TPO in nonthrombocytopenic term and preterm infants 414t
pregnancy termination, anti-D 101
preservatives, anticoagulant–preservative (AP) solutions 351–352
primitive neuroectodermal tumor (PNET) 394
prion disease, transfusion-related 368
propionic acidemia 226
proplatelets 189t, 190
formation 190t
prostacyclin, in IDM 13
protein C
activated (APC) 325
deficiency 327–328
and DIC 322
protein S deficiency 327, 328
prothrombin
deficiency 6, 310, 315
gene G20210A 326
prothrombin complex concentrates (PCC) 315
prothrombin time 311
prothrombotic disorders 325–328
protoporphyrin 18
infants 1–7 months 412t
protoporphyrin/heme ratio 61, 62
pseudo von Willebrand disease 196–197
pulmonary disease, transfusion 351t
pulmonary hypertension 226
pure white cell aplasia 265
purine salvage pathway dysfunction in SCID 293–294
purpura fulminans 327–328
pyknocytosis 137–138
pyrimidine 5'nucleotidase (P5'N) deficiency 147
pyropoikilocytosis (HPP) 138t, 141
pyroxidine deficiency 80
pyruvate kinase deficiency 146–147
pyknocytosis 137

radial dysplasia, TAR syndrome 219
radial hypoplasia, and thrombocytopenia 225
radiation therapy
FA 74
in pregnancy 15
RANTES 284
red blood cell transfusions 59, 350–351
2, 3-DPG in 352
formulae for transfusion 354t
paternal 355
PRBC infusion issues 353
PRBC shelf life 352, 354–355
whole blood reconstitution 354t, 353–354
see also packed RBCs
red blood cells *see* erythrocytes
red cell distribution width (RDW) 2
renal failure, platelet function 198
renal tubular disease 156
renal tumors 396
clear cell sarcoma 397
mesoblastic nephroma 396
rhabdoid tumor 397
WAGR 396
Wilms tumor 396–397
renal vein thrombosis 226, 330
IDM 13
respiratory burst activity, PMNs 262
respiratory distress syndrome 108, 110
reticular dysgenesis 77
reticulocytes
cord blood percentage, preterms 412t
count 133, 410
and cord clamping 410
retinal hemorrhage 327
retinoblastoma 395
reviparin
dosage 332t
monitoring nomogram 333t
prophylaxis 332t
Rh antibodies, formation 5
Rh antigens 92–94
C/c antigens 93–94, 116–117
E/e antigens 93, 116–117
Rh-related antigen LW 94
RhD gene and antigen 93t, 92–94
Rh factor 4–5
RhCE and RhD 93t
rhabdoid tumor of kidney 397
rhabdomyosarcoma 394
RhAG, Rh-associated glycoprotein 93
RhCE gene and antigen 92, 93t
RhD
algorithm, approach to management 109t
anti-RhD

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

dose (by country/timing) 102t
dose and response 100
half-life 101
and HDN 116
IAT titer 104
postnatal injection 100, 101
pre- and postnatal clinical trials 101
prophylaxis against sensitization 97, 101
standard dose 102
epitopes 92–93
frequency 92
decrease in immunization rate of at-risk mothers 101
'grandmother theory' 102
and HDN 91–92
in vitro fertilization 102
nonresponders 97
see also hemolytic disease of newborn (HDN)
rhEPO therapy
for anemia of prematurity 59–60
cost 60
with parenteral iron 62
side effects 60
trials 60
Roberts syndrome 220
comparison with other syndromes 221t
rubella 25–26
hematologic manifestations 25

S antigen, HDN 119
sacrococcygeal teratoma 386–387
sarcomas
schistocytic anemia 136
DIC 136
schizocytes 410t
sclerosing agents 218
screening
G6PD deficiency 145
hemoglobinopathies 163–168
phenylketonuria 163
sickle cell syndromes 163, 164
thalassemia syndromes 166
screening programs 164–168
Sebastian syndrome 224
Seckel syndrome 80
secretory platelet disorders 197
serine proteinase inhibitors 327
severe combined immunodeficiency disorders (SCID) 293
IV IgG replacement therapy 301
with hypereosinophilia 294
Ig and lymphocyte profiles 295t
purine salvage pathway dysfunction 293–294
therapy 301
X-linked SCID 293, 301
see also ADA; Omenn syndrome; Zap-70 deficiency
severe congenital neutropenia (SCN) 77
international registry 77
shear rate *see* blood viscosity
Shwachman–Diamond(–Oski) syndrome 76, 265
sialic acid/sialoglycoproteins 136
sickle cell syndromes 153–154
hemoglobin S-C disease 153
infants of mothers with S-C disease 154
screening 163, 165t, 164–166
sickle beta° thalassemia 153
sickle cell anemia 153–154
sideroblastic anemia 50, 72, 79–80
signal transduction pathways, X-linked SCID 293
Singer 1-minute alkali denaturation test 3
sinovenous thrombosis 330
Sjogren syndrome 204
small-for-gestational age (SGA) infant, thrombocytopenia 226
smoking 16
passive 16
Sn-mesoporphyrin 145
solvent detergent (SD) treated plasma 361
spectrin
erythrocyte cell membrane 45t
spherocytosis (HS) 140t
spherocytes *see* hereditary spherocytosis (HS)
spherocytosis (HS) 138, 138t, 140t, 139–141
splenic sequestration crisis 154
splenomegaly, in HS 139
Ss blood group system 95–96
SS-A, anti-Ro 15
SS-B, anti-La 15
Staphylococcus aureus, coagulase negative 216
stem cell transplantation, donor availablity 376
stem cells 40–42
aortic–gonadal–mesonephric (AGM) region 41
erythropoiesis 41t
megakaryocytopoiesis–thrombocytopoiesis 188t
transplantation 72, 75, 76
see also cord stem cell transplantation
storage pool defects 197
Streptococcus pneumoniae infection 136
B beta-hemolytic 215
T-cell dysfunction 287
splenectomy 141

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

streptokinase 334t, 333–334
stress
  labor-induced 261–262
  and PMNs 261–262
sulfonamides, thrombocytopenia 204
superoxide dismutase 46
surfactant 108
syphilis 22–23
  congenital 23

T cells 286–288
  absence of memory T cells 286
  and combined immunodeficiency 291–292
  cytolytic activity decrease 288
  naive phenotype 287
  specific immunodeficiency
    associated conditions 294
    laboratory findings 299
    management 300–302
    thymus size 299
  subpopulations, neonates and infants 287t, 288t
T-activation 136–137, 365
  suspected 136
T-cell receptor diversity 287
TAR syndrome *see* thrombocytopenia and absent radii (TAR) syndrome
teratoma 386–387
thalassemia syndromes 148
  alpha thalassemia 148–151
    genotypes 149t
    homozygous (hydrops) 150–151
    screening 167t, 166–167
    trait 149
  beta thalassemia 151–152
    homozygous 151–152
  gamma thalassemia 153
  hemoglobin E/beta thalassemia 152–153
  hemoglobin H disease 149–150
  hydrops fetalis 3
  screening 166, 166t
  silent carrier state 149
thiazides, thrombocytopenia 204
Thompsen–Friedenreich antigen 365
thrombasthenia, Glanzmann 196t, 195–196
thrombin
  activation of platelets 194
  and arachidonic acid 195
  arachidonic acid production 195
thrombin receptor 191
thrombocytopenia 198–228
  amegakaryocytic 77, 223–224
  diagnostic approach 227–228, 229t
  drug-associated 205t, 204–205
  etiology
    chemotherapy 17
    in sick newborn 228t
  heparin-induced (HIT) 17, 205
  immune 200
  incidence 207t
  infant of diabetic mother (IDM) 13
  infant of hypertensive mother (IHM) 14
  infections 215–216
  inherited disorders 225t, 218–225, 228
    X-linked 225
    chromosomal abnormalities 217
  isolated perinatal, secondary to maternal ITP 202–203, 359
  malformations 217–218
  maternal thrombocytopenia 200–203
    causes 200
    diagnostic approach in infant 229t
    drug-associated 205t, 204–205
    gestational 201
    platelet count 228
  mechanism 206t
  metabolic disorders 225–226
  neonatal autoimmune (NITP) 361
  pseudothrombocytopenia 413–417
  severe, defined 227
  transient 15
  treatment 227–228
  see also neonatal alloimmune thrombocytopenia (NAIT)
thrombocytopenia and absent radii (TAR) syndrome 50, 77, 80, 219–223
  comparison with other syndromes 221t
  features, compared with other studies 222t
  pathogenesis 222–223
  prognosis 220–222
  storage pool defects 197
  treatment 223
thrombocytopenia and radio-ulnar synostosis 223
thrombocytopoiesis 188t
thrombocytosis 228–230
  essential (ET) 230
thromboembolic disorders 325
  catheter-related 329–330
  etiology 325

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

non-catheter-related 330
prothrombotic disorders 325–328
thrombolytic therapy 331–334
agents 334t, 333–334
thrombopoietin receptor (c-mpl) 190, 222–223, 224
mutations 224
thrombopoietin (TPO)
elevated
in cord blood 215
thrombocytosis 228
measurement 414
in nonthrombocytopenic term and preterm infants, mothers with pre-eclampsia 414t
thrombosis
IDM 13
infant of diabetic mother (IDM) 13
thrombotic thrombocytopenic purpura (TTP) 29, 50
in pregnancy 202
purpura fulminans 327–328
thromboxane A2 (TxA2) 194
thymic hypoplasia 299
thymus, immune reconstitution 381
tissue plasminogen activator (tPA) 333, 334t
tolbutamide, thrombocytopenia 205
TORCH syndrome 216
total parenteral nutrition, rhEPO in 60
toxoplasmosis 20–22
TPN *see* total parenteral nutrition
tranexamic acid 218, 325–334
transcobalamin deficiency 50, 81
transferrin receptor 18, 61
infants 1–7 months 412t
measurement 412
transferrin saturation ratio 412
transfusion 349–369
adverse reactions 364–369
hemolytic reactions 364–365
infections 367–369
leukocyte alloimmunization 365
lung injury (TRALI) 365
metabolic 366–367
TAGVHD 355, 365–366
autologous 356
complications 354–355
current risk estimates 367t
directed donor transfusions 355
emergency 110
multiple, donor exposure 354–355
pre-transfusion testing 349–350
see also exchange –; feto-maternal –; maternal –; platelet –; *and named products*
transient erythroblastopenia of childhood (TEC) 71
transient hypogammaglobulinemia of infancy (THI) 290
diagnosis 296–297
evaluation 298
in trisomies 291
transient myeloproliferative disorder 390, 391–393
hydrops fetalis 391
spontaneous regression 393
treponemal antibody tests 23
triose phosphate isomerase (TPI) deficiency 147
trisomies
hypogammaglobulinemia of infancy (THI) 291
and thrombocytopenia 217
tumor necrosis factor (TNF)
and thrombocytopenia 217
TNF-alpha 283
Turner syndrome 81, 217, 290
twin–twin transfusion syndrome (TTS) 11–12
incidence 11
management 12
tyrosine kinase receptors 191

ultrasound, in HDN 105
umbilical arterial catheters, thromboembolic events 329
umbilical cord
damage 10
delayed clamping 59, 356, 406, 409
mummification 270
see also cord blood; cord stem cells
umbilical stump, excessive hygienic care 270
umbilical venous catheters, thromboembolic events 329
Upshaw–Schulman syndrome 226
uridinediphosphoglucuronate glucuronosyltransferase (UDPGT-1) 110–112, 145
and breastfeeding 111
mutations 111–112
urokinase 333, 334t

vaccines
recommendations
antibody deficiency 298
immune deficiency 301

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521780705 - Neonatal Hematology
Edited by Pedro A. de Alarcon and Eric J. Werner
Index
More information

vanillylmandelic acid (VMA) 387
vascular anastomoses 11
velamentous cord insertion 10, 11, 49
venous catheters, thromboembolic events 329
viral infections 23–30
vitamin B12 deficiency 19–20
  measurement 413
vitamin E deficiency 137
  pyknocytosis 137
  supplementation 137
vitamin K
  mechanism of action 319
  prophylactic administration 320–321, 325
    recommendations 321t
  sources 319
vitamin K deficiency 16, 319–321
  clinical presentation 319, 320t
  historical aspects 6
  IVH 325
  treatment 319–320
von Willebrand disease 416
von Willebrand factor receptor (vWFR) 191, 192
  adhesion 193
  defect, Bernard–Soulier syndrome 195
  pseudo vWD 196
von Willebrand factor (vWF)
  deficiency 316
    prenatal diagnosis 311
    vWF–factor VIII replacement therapy 317t
  vWF-mediated binding of collagen 193t

Wilms tumor 396–397
Wiskott–Aldrich syndrome 197, 224–225, 292–293
  complications 301

X-linked agammaglobulinemia (XLA) 265, 289–290
  diagnosis 297
X-linked and other SCID 293, 301
X-linked thrombocytopenias 225

yolk-sac
  hematopoiesis 42, 42t, 254–255
  progenitors vs. age of development 427t
yolk-sac endoderm 41
yolk-sac tumor 386

Zap-70 deficiency 300
zidovudine 29
zinc deficiency 51
zinc protoporphyrin *see* protoporphyrin

© Cambridge University Press www.cambridge.org